The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR).

The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least.

This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.

• Atypical Antipsychotic (Drug), also known as olanzapine, quetiapine , ziprasidone and risperidone: Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
• atypical antipsychotic combined with MECT (Other), also known as MECT means modified electric convulsive therapy: The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness

Primary outcomes

• the Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [before the treatment]: the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection
• the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [Change from Baseline expression level at 4-week treatment]: the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection
• the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [Change from Baseline expression level at 8-week treatment]: the plasma samples will be collected from the patients with schizophrenia at the 8-week treatment for the microRNA-30e detection

Secondary outcomes

• the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia [before, after 4 weeks and 8 weeks treatment]: The PANSS for estimating the severity of positive and negative symptoms in schizophrenia
• The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia [before, after 4 weeks and 8 weeks treatment]: The degree of Personal and Social Performance scale(PSP) used to evaluate the disable levels in Multiple dimensions ,especially in social and self-care performance
• The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment [4 weeks and 8 weeks treatment]: Main purpose to provide a global rating of illness severity ,improvement and response to treatment for the patients with schizophrenia

Sex: All, ages: 17 Years to 40 Years, accepts healthy volunteers

Inclusion Criteria:

* Persons should be diagnosed with schizophrenia according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)
* The first-onset or drug-free in the latest 3 months
* Between the ages of 17-40

Exclusion Criteria:

* Comorbid with other psychosis
* Have physical or neurological diseases such as traumatic brain injuries
* History of drug-abused or alcoholic
* Blood transfusion history in a month
* Been treated with Modified Electric Convulsive Therapy(MECT) in late 3 months

• Results publication: Xu C, Liu X, Song X, Gao Q, Cheng L, Wang L, Zhang K, Xu Y. Aberrant resting state in microRNA-30e rat model of cognitive impairment. Neuroreport. 2016 Aug 3;27(11):809-17. doi: 10.1097/WNR.0000000000000616. PMID 27258654
• Results publication: Xu Y, Li F, Zhang B, Zhang K, Zhang F, Huang X, Sun N, Ren Y, Sui M, Liu P. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr Res. 2010 Jun;119(1-3):219-27. doi: 10.1016/j.schres.2010.02.1070. Epub 2010 Mar 27. PMID 20347265
• Results publication: Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, Schmitt A, Schneider A, Cabral H, Cagsal-Getkin O, Vanderburg CR, Delalle I. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One. 2013;8(1):e48814. doi: 10.1371/journal.pone.0048814. Epub 2013 Jan 30. PMID 23382797

• Shoufu Xie, postgraduate, Principal investigator, Dalian Seventh People's Hospital